This was a positive announcement, once they get this approval that opens up another 20% revenue in Europe and we already know CUV in EPP has another 97/98% target market to get treated.
Plenty in this one trick pony in Revs and profit until they roll out further indications and the OTC.
Ann: CLINUVEL submits label expansion for adolescent EPP patients, page-11
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
0.100(0.68%) |
Mkt cap ! $741.5M | |||
| Open | High | Low | Value | Volume |
| $14.60 | $15.00 | $14.31 | $1.171M | 78.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 568 | $14.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.85 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$14.78 |
Change
0.100 ( 0.48 %) |
||||
| Open | High | Low | Volume | ||
| $14.81 | $15.00 | $14.54 | 5844 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| CUV (ASX) Chart |